The latest deal for a molecular glue degrader (MGD) technology has the biggest upfront payment yet. Novartis is paying Monte Rosa Therapeutics a hefty $150m for global rights to products including MRT-6160, intended for immune-mediated conditions.
Novartis Pays Big To License Monte Rosa’s Molecular Glue Degrader
Unlike previous deals in this space which were mostly to do with discovering new compounds, the big pharma is paying $150m upfront to license a specific product.
More from Deals
More from Therapy Areas
• By
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.